Adrenergic pathway activation enhances brown adipose tissue metabolism: A [18F]FDG PET/CT study in mice

Nuclear Medicine and Biology

Volumn 41, Issue 1, 2014, Pages 10-16

  Mirbolooki, M Reza ^a   Upadhyay, Sanjeev Kumar ^a   Constantinescu, Cristian C ^a   Pan, Min Liang ^a   Mukherjee, Jogeshwar ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BAT; Brown fat; Diabetes; Molecular imaging; Obesity

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ATOMOXETINE; FLUORODEOXYGLUCOSE F 18; FORSKOLIN;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ARTICLE; BRAIN; BROWN ADIPOSE TISSUE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; HEART; IMAGE ANALYSIS; IMAGE PROCESSING; LIVER; MALE; MOLECULAR IMAGING; MOUSE; MUSCLE; NON INVASIVE PROCEDURE; NONHUMAN; RADIOLOGICAL PARAMETERS; SECOND MESSENGER; SPLEEN; STANDARD UPTAKE VALUE; THREE DIMENSIONAL IMAGING; TISSUE METABOLISM; WHITE ADIPOSE TISSUE;

BAT; BROWN FAT; DIABETES; MOLECULAR IMAGING; OBESITY;

ADIPOSE TISSUE, BROWN; ADRENERGIC AGONISTS; ANIMALS; FLUORODEOXYGLUCOSE F18; MALE; MICE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ADRENERGIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84888344256     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.08.009     Document Type: Article

References (35)

1. Nedergaard J., Bengtsson T., Cannon B. New powers of brown fat: fighting the metabolic syndrome. Cell Metab 2011, 13(3):238-240.
2. De Matteis R., Ricquier D., Cinti S. TH-, NPY-, SP-, and CGRP-immunoreactive nerves in interscapular brown adipose tissue of adult rats acclimated at different temperatures: an immunohistochemical study. J Neurocytol 1998, 27(12):877-886.
3. Inokuma K., Ogura-Okamatsu Y., Toda C., Kimura K., Yamashita H., Saito M. Uncoupling protein 1 is necessary for norepinephrine-induced glucose utilization in brown adipose tissue. Diabetes 2005, 54(5):1385-1391.
4. Garnock-Jones K.P., Keating G.M. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009, 11(3):203-226.
5. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27(5):699-711.
6. Lin S.F., Fan X., Yeckel C.W., Weinzimmer D., Mulnix T., Gallezot J.D., et al. Ex vivo and in vivo evaluation of the norepinephrine transporter ligand [(11)C]MRB for brown adipose tissue imaging. Nucl Med Biol 2012, 39(7):1081-1086.
7. Mirbolooki M.R., Constantinescu C.C., Pan M.L., Mukherjee J. Targeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity. Synapse 2013, 67(2):79-93.
8. de Jesus L.A., Carvalho S.D., Ribeiro M.O., Schneider M., Kim S.W., Harney J.W., et al. The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J Clin Invest 2001, 108(9):1379-1385.
9. Kitao N., Hashimoto M. Increased thermogenic capacity of brown adipose tissue under low temperature and its contribution to arousal from hibernation in Syrian hamsters. Am J Physiol Regul Integr Comp Physiol 2012, 302(1):R118-R125.
10. Yoshida T., Sakane N., Wakabayashi Y., Umekawa T., Kondo M. Anti-obesity and anti-diabetic effects of CL 316,243, a highly specific beta 3-adrenoceptor agonist, in yellow KK mice. Life Sci 1994, 54(7):491-498.
11. 18F]FDG PET/CT and β3-adrenergic receptor activation. EJNMMI Res 2011, 1(1):30.
12. van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., Drossaerts J.M., Kemerink G.J., Bouvy N.D., et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009, 360(15):1500-1508.
13. 18F]FDG micro-PET/CT. J Vis Exp 2012, (69). 10.3791/4060.
14. Baba S., Jacene H.A., Engles J.M., Honda H., Wahl R.L. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med 2010, 51(2):246-250.
15. Michel M.C., Harding S.E., Bond R.A. Are there functional beta(3)-adrenoceptors in the human heart?. Br J Pharmacol 2011, 162(4):817-822.
16. Insel P.A., Ostrom R.S. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol Neurobiol 2003, 23(3):305-314.
17. Au-Yong I.T., Thorn N., Ganatra R., Perkins A.C., Symonds M.E. Brown adipose tissue and seasonal variation in humans. Diabetes 2009, 58(11):2583-2587.
18. Cypess A.M., Lehman S., Williams G., Tal I., Rodman D., Goldfine A.B., et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009, 360(15):1509-1517.
19. Stefan N., Pfannenberg C., Haring H.U. The importance of brown adipose tissue. N Engl J Med 2009, 361(4):416-417. [author reply 8-21].
20. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004, 84(1):277-359.
21. Granneman J.G., Lahners K.N. Differential adrenergic regulation of beta 1- and beta 3-adrenoreceptor messenger ribonucleic acids in adipose tissues. Endocrinology 1992, 130(1):109-114.
22. Langin D., Tavernier G., Lafontan M. Regulation of beta 3-adrenoceptor expression in white fat cells. Fundam Clin Pharmacol 1995, 9(2):97-106.
23. Lafontan M., Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993, 34(7):1057-1091.
24. McMahon K.K., Schimmel R.J. Apparent absence of alpha-2 adrenergic receptors from hamster brown adipocytes. Life Sci 1982, 30(14):1185-1192.
25. Elfellah M.S., Reid J.L. Identification and characterisation of beta-adrenoceptors in guinea-pig skeletal muscle. Eur J Pharmacol 1987, 139(1):67-72.
26. Challiss R.A., Leighton B., Wilson S., Thurlby P.L., Arch J.R. An investigation of the beta-adrenoceptor that mediates metabolic responses to the novel agonist BRL28410 in rat soleus muscle. Biochem Pharmacol 1988, 37(5):947-950.
27. Roberts S.J., Summers R.J. Cyclic AMP accumulation in rat soleus muscle: stimulation by beta2- but not beta3-adrenoceptors. Eur J Pharmacol 1998, 348(1):53-60.
28. Shabalina I.G., Backlund E.C., Bar-Tana J., Cannon B., Nedergaard J. Within brown-fat cells, UCP1-mediated fatty acid-induced uncoupling is independent of fatty acid metabolism. Biochim Biophys Acta 2008, 1777(7-8):642-650.
29. Oana F., Takeda H., Matsuzawa A., Akahane S., Isaji M., Akahane M. Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonist. Eur J Pharmacol 2005, 518(1):71-76.
30. Yilmaz Y., Ones T., Purnak T., Ozguven S., Kurt R., Atug O., et al. Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans. Aliment Pharmacol Ther 2011, 34(3):318-323.
31. Coman O.A., Paunescu H., Ghita I., Coman L., Badararu A., Fulga I. Beta 3 adrenergic receptors: molecular, histological, functional and pharmacological approaches. Rom J Morphol Embryol 2009, 50(2):169-179.
32. Baker J.G. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005, 144(3):317-322.
33. Weyer C., Tataranni P.A., Snitker S., Danforth E., Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 1998, 47(10):1555-1561.
34. Storstein L. Non-receptor-mediated inotropic drugs. Eur Heart J 1988, 9(Suppl H):91-93.
35. Arch J.R. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 2002, 440(2-3):99-107.